EHJ-CVP Editor-in-Chief
@EditorEHJCVP
Followers
388
Following
243
Media
29
Statuses
156
#EHJPharmacotherapy Editor-in-Chief X account. Posts by @AgewallStefan and his team. @ESC_Journals #PharmaPulse #pharmacotherapy #cardiology #cardioed
Joined February 2024
RT @escardio: Happening now: #ESCardioCRT is underway with a discussion focused on clear actions and pathways to be created for the improve….
0
3
0
RT @FeliceGragnano: Prevention of #AFib with SGLT2-I across the spectrum of cardiovascular disorders: a meta-analysis of RCTs 📊. 🔗 https://….
0
4
0
RT @ESC_Journals: 🆕 Long-term Antiplatelet Monotherapy after PCI: Searching for the smart choice 🔥 A new #Pharmapulse now online in #EHJPha….
0
12
0
RT @ESC_Journals: 🧠 Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with AF: new data from the GLORIA-AF r….
0
34
0
RT @escardio: Looking back to our first meeting in 1949, the ESC is proud to celebrate a legacy of global members who contribute so much.….
0
8
0
RT @FeliceGragnano: 🧠💊 Is clopidogrel a *smart choice* for long-term antiplatelet monotherapy in patients with coronary artery disease? We….
0
9
0
Early use of SGLT2i after myocardial infarction.
🆕 Early use of #SGLT2i after myocardial infarction shows promise in reducing HF hospitalisations, but no mortality benefit 🚑❌⚰️ Is it time to rethink post-MI therapy? 🤔 Read more in #EHJPharmacotherapy 👉 . @EditorEHJCVP @FeliceGragnano @MattiaGalli10
0
1
1
Interesting data.
🧠💊 Is clopidogrel a *smart choice* for long-term antiplatelet monotherapy in patients with coronary artery disease? We share our perspective in our latest article in #EHJPharmacotherapy! 📖🔍. 👉 @paolocalabro1 @v_desio @MattiaGalli10 @EditorEHJCVP.
0
0
0
Is albumin level associated with risk of major bleeding in patients with Afib on DOACs?.
Albumin level and risk of major #bleeding in patients with #AFib on DOACs 🩸 New evidence now published with open access in #EHJPharmacotherapy 💊 . 📡 @EditorEHJCVP @ESC_Journals @escardio @ESCWGThrombosis . #Cardiology #CardioEd #CardioTwitter.
0
2
6
RT @escardio: Be where digital transformation happens. #ESCAIsummit2025 is the gateway for cutting-edge digital solutions that are shaping….
0
17
0
RT @AgewallStefan: Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.
0
1
0
SHould we use colchicine in patients with MI?.
#Colchicine in STEMI: #CLEAR results, #cloudy impact. What do the conflicting results tell us❓.Do we need further studies❓.Is there an optimal patient #phenotype❓. 📍More at #EHJPharmacotherapy ➡️ #CardioX #Cardiology #Heart.@EditorEHJCVP @ESC_Journals
0
1
3
RT @MattiaGalli10: Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary….
0
5
0
Triple lipid lowering drugs.
Is triple therapy with statin, ezetimibe and bempedoic acid an option?.Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia @FeliceGragnano @EditorEHJCVP @pyrpyris .
0
1
1
The EMPAG-HF trial unveils the acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography in patients with HF.
0
2
5
Frail persons are for sure a certain group of paetins.
Can we use DOAC in frail patients?.
0
0
2
🔬🩺 How does #BMI influence the kidney-protective effects of #SGLT2 inhibitors in diabetes? 📢 A nationwide study published in #EHJPharmacotherapy reveals new insights for personalized treatment strategies. Read more 👉 @FeliceGragnano @ESC_Journals.
0
4
9
🫀🔬 New insights on #antithrombotic therapy after #bioprosthetic mitral valve replacement. What are the latest findings? How can they impact clinical practice? 📢 A new study is out in #EHJPharmacotherapy. Don’t miss it! 👉 @FeliceGragnano @ESC_Journals
1
10
23
RT @FeliceGragnano: 🚨 Breaking News #EHJPharmacotherapy!. A new study reveals that adding GLP-1 RA to SGLT2-I significantly reduces the ris….
0
5
0